A Pilot Open-Label Study of the Efficacy and Safety of Imetelstat (GRN163L) in Myelofibrosis and Other Myeloid Malignancies

Trial Profile

A Pilot Open-Label Study of the Efficacy and Safety of Imetelstat (GRN163L) in Myelofibrosis and Other Myeloid Malignancies

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Imetelstat (Primary)
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Sponsors Geron Corporation; Janssen Research & Development
  • Most Recent Events

    • 16 Jun 2017 Planned primary completion date changed from 1 May 2017 to 16 Jan 2019.
    • 02 Dec 2016 Planned End Date changed from 1 May 2018 to 1 Jan 2019.
    • 22 Jun 2016 Planned primary completion date changed from 1 Mar 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top